<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML xmlns:o = "urn:schemas-microsoft-com:office:office"><HEAD>
<META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<META content="MSHTML 6.00.2900.2873" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff>
<DIV>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
size=3>Estimadas y estimados</FONT></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
size=3>esta disponible el</FONT></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold">WHO
Pharmaceuticals Newsletter (No. 3, 2006), </SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><B><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
face="Times New Roman"></FONT></SPAN></B> </P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><B><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
face="Times New Roman">cuyo indice es</FONT></SPAN></B></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><B><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
face="Times New Roman"></FONT></SPAN></B> </P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><B><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
face="Times New Roman">Regulatory Matters<o:p></o:p></FONT></SPAN></B></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Acetylcysteine
</SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
New paediatric dosing information
........................................................................
1<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Anabolic
steroids </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Not to be sold as dietary supplements
..............................................................
1<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Denileukin
diftitox </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Label to include reports of visual loss
.............................................................
1<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">l-Arginine
</SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Not for heart patients
..................................................................................................
1<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Pegaptanib
sodium </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Reports of anaphylaxis/anaphylactoid
reactions.............................................. 2<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><B><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
face="Times New Roman">Safety of Medicines<o:p></o:p></FONT></SPAN></B></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Bowel
cleansing oral sodium phosphates </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Risk of renal damage ..........................................
3<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Glucosamine
products </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
86 reports to date in
Sweden.................................................................
3<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Isotretinoin
</SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Suspected association with vascular disorders
.............................................................
3<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Mifepristone
</SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Two additional sepsis
deaths....................................................................................
3<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Miracle
Bion </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Risk of </SPAN><I><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana-Italic; mso-bidi-font-family: Verdana-Italic"><FONT
face="Times New Roman">E.coli </FONT></SPAN></I><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">contamination
.....................................................................................
4<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Pimecrolimus
and tacrolimus </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Cautious use recommended.......................................................
4<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Polygonum
multiflorum </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Risk of liver
effects.............................................................................
4<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Yohimbine-containing
products </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">--
Dangerous in high-risk groups ...............................................
4<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><B><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><FONT
face="Times New Roman">Feature<o:p></o:p></FONT></SPAN></B></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 11pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">New
Challenges in Safety of Medicines: highlights from the Twelfth
International<o:p></o:p></SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 11pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">Conference
of Drug Regulatory Authorities </SPAN><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana">................................................................................
6</SPAN></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"></SPAN> </P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"><FONT
face=Arial></FONT></SPAN><FONT size=2>la direccion es</FONT></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><FONT
face=Arial><FONT size=2><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"><A
href="http://www.who.int/entity/medicines/publications/newsletter/pn2006_3.pdf">http://www.who.int/entity/medicines/publications/newsletter/pn2006_3.pdf</A></SPAN></FONT></FONT></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><FONT
face=Arial><FONT size=2><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"><FONT
face=Arial size=2></FONT></SPAN></FONT></FONT> </P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><FONT
face=Arial><FONT size=2><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"><FONT
face=Arial size=2>saludos</FONT></SPAN></FONT></FONT></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><FONT
face=Arial><FONT size=2><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"><FONT
face=Arial size=2>Martín Cañás<BR>GAPURMED<BR><A
href="mailto:macanas@netverk.com.ar">macanas@netverk.com.ar</A></FONT></SPAN></FONT></FONT></P>
<P class=MsoNormal
style="MARGIN: 0cm 0cm 0pt; mso-pagination: none; mso-layout-grid-align: none"><FONT
face=Arial><FONT size=2><SPAN
style="FONT-SIZE: 9pt; COLOR: black; FONT-FAMILY: Verdana; mso-bidi-font-family: Verdana"><FONT
face=Arial size=2><A
href="mailto:macanas@netverk.com.ar"></A></FONT></SPAN><SPAN
style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Verdana-Bold; mso-bidi-font-family: Verdana-Bold"><o:p></o:p></SPAN></FONT></FONT></P></DIV></BODY></HTML>